Interactions between neurotensin receptors and G proteins. by Pelaprat, Didier
Interactions between neurotensin receptors and G
proteins.
Didier Pelaprat
To cite this version:
Didier Pelaprat. Interactions between neurotensin receptors and G proteins.. Peptides / Pep-
tides (Fayetteville), 2006, 27 (10), pp.2476-87. <10.1016/j.peptides.2006.04.027>. <inserm-
00519739>
HAL Id: inserm-00519739
http://www.hal.inserm.fr/inserm-00519739
Submitted on 21 Sep 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1  
 
Interactions between neurotensin receptors and G proteins 
Didier PELAPRAT
a, b*
 
 
a
 U773 INSERM, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, BP416, 75870 
Paris Cedex 18, France. 
b
 EA 3512, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, BP416, 75870 Paris 
Cedex 18, France. 
 
* Corresponding author: 
Dr Didier PELAPRAT 
U773 INSERM,  
Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard,  
BP416,  
75870 Paris Cedex 18, France. 
Tel: (33)-1-44-85-63-10; fax: +33-1-44-85-63-06; Email address: pelaprat@bichat.inserm.fr 
 
 2  
Abstract: 
Three neurotensin (NT) receptors have been cloned to date, two of which, NTS1 and 
NTS2, belonging to the family of seven transmembrane domain receptors coupled to G 
proteins (GPCRs). NTS1 and NTS2 may activate multiple signal transduction pathways, 
involving several G proteins. However, whereas NT acts as an agonist towards all NTS1-
mediated pathways, this peptide exerts agonist or antagonist activities depending on the 
considered NTS2-mediated pathway. Studies on these receptors reinforce the concept of 
independence between multiple signals potentially mediated through a single GPCR, 
generating a wide diversity of functional responses depending on the host cell and the ligand. 
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1. Introduction: 
 Neurotensin (NT), a 13-aminoacid peptide [13], acts as a neuromodulator in the brain 
and a paracrine or circulating hormone in periphery [38,74]. NT agonists or antagonists have 
been suggested to be of potential use for the treatment of pain, eating disorders, psychotic 
troubles, drug abuse and stress [6,36,64, 37]. Moreover, NT acts as a growth factor on 
different classes of normal and cancer cells, and NT-related ligands are proposed to represent 
valuable tools for tumor targeting [29,61]. 
Results from binding and pharmacological experiments have suggested the existence 
of different subtypes of NT receptors. For instance, two classes of NT binding sites were 
evidenced in rodent tissues, differing in affinity for NT and ability to bind the antihistamine 
drug, levocabastine [39,67]. The "high affinity site" (0.1-0.3 nM) was sensitive to Na
+
 and 
GTP, did not bind levocabastine and showed a peak of expression around birth in some brain 
structures. The "low affinity site" (1-5 nM) was less sensitive to Na
+
 and insensitive to GTP, 
bound levocabastine with high affinity (in rodent but not in human) and was more evenly 
distributed in brain structures, where its expression increased gradually until adulthood. 
Furthermore, NT analogs presented different relative potencies to elicit various 
pharmacological effects, such as modulation of dopaminergic transmission, hypothermia or 
analgesia, and these effects were differentially affected by antagonists [37,41].  
The diversity of NT receptors has been confirmed through cloning experiments. Three 
NT receptors, termed NTS1, NTS2 and NTS3 (also referred to as NTR1, NTR2 or NTR3) 
have been cloned to date. NTS1 and NTS2 belong to the family of receptors with seven 
transmembrane spanning domains and coupled to G proteins (GPCRs), whereas NTS3 
belongs to the family of sorting receptors [37,74].  
Similarly to the previously reported "high affinity NT binding site", the rat and human 
NTS1s (424 and 418 amino acids, respectively) did not bind levocabastine and presented Na
+
- 
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and GTP-sensitive NT binding sites [72,75]. Mutagenesis and molecular modeling studies 
revealed partial overlap between binding sites for NT and for the antagonist SR 48692 on rat 
NTS1 [5,37,40,57]. Residues Met208 in the fourth transmembrane domain (TM4) and Phe331 
and Arg327 in TM6 interacted with both ligands. The SR 48692 binding site was located in an 
hydrophobic pocket involving other residues in TM6 and TM7, while the NT binding site 
resided closer to the extracellular side and encompassed additional interactions with residues 
in the third extracellular domain. Sodium sensitivity of agonist binding was born by Asp113 
in TM1 [45]. 
Rodent [15,49] and human [76] NTS2s (416 and 410 amino acids, respectively) share 
only around 40% amino acid identities with the corresponding NTS1s, have shorter N-
terminal extracellular tails and longer third intracellular loops. NTS2 corresponds to the 
previously described "low affinity NT binding site". Rodent NTS2s bind the histamine H1 
antagonist levocabastine with high affinity, whereas human NTS2 presents lower affinity for 
this compound [15,49,76]. Affinity of NT for NTS2 is poorly sensitive to Na
+ 
and insensitive 
to GTP. Na
+
-insensitivity was attributed to replacement of the Asp113 residue of rat NTS1 by 
Ala or Gly residues in corresponding positions of rat and human NTS2s, respectively [45].  
By contrast with both NTS1 and NTS2, NTS3 belongs to the family of proteins 
characterized by a single transmembrane domain, a cysteine-rich domain and a short 
cytoplasmic C-terminal tail [50]. This 100-kDa protein was previously identified as sortilin, a 
protein involved in molecule sorting between the cell surface and intracellular compartments 
[48,58]. 
Investigations on the respective role of these receptors in mediating the effects of NT 
were greatly helped by the development of nonpeptide NTergic ligands such as SR 48692 
[24]. This compound, first identified as a NTS1 antagonist, presented a higher affinity for this 
receptor than for NTS2, while the analog SR 142948A did not discriminate between these two 
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receptors [25]. Experiments performed with these compounds [25,37,71] as well as 
intracerebral injection of anti-receptor antisense oligonucleotides [19] or evaluation of knock-
out mice [59], suggested that most of the NT effects could be attributed to stimulation of 
NTS1. However, the functional importance of NTS2 and NTS3 might still be largely 
underestimated. Several arguments suggest that NTS2 mediates analgesic effects of NT 
[19,44,81]. Recent data otherwise revealed a role of NTS3 in mediating NT effects on 
microglial migration, cytokine/chemokine expression and proliferation of cancer cell lines 
[17,18,47]. NTS3/sortilin was also found to be a co-receptor of p75NTR, mediating pro-NGF-
induced apoptosis [54]. 
Interactions between NT receptors and G proteins were suggested through pioneering 
works showing that NT induced inositol phosphate (InsP) production [1,22,70], inhibited 
cAMP formation [10], and that the "high affinity NT binding site" was sensitive to guanine 
nucleotides [12]. Molecular studies thereafter indicated that most of these effects were 
attributable to NTS1. Since a majority of studies were performed on that receptor, this topic 
will represent a large part of this review. However, NTS2 also interacts with G-proteins, at 
least in some systems, and its striking differences with NTS1 at both molecular and functional 
levels, among which the finding that NT may behave as a NTS2 antagonist, raise fascinating 
questions. Furthermore, although not directly interacting with G proteins, NTS3 may 
modulate some of the G protein-dependent responses associated with NTS1 [46]. Moreover, 
NTS3 mRNA was detected in CHO cells [21]. Therefore, a possible involvement of this 
receptor in several effects solely attributed up to now to the other NT receptors has always to 
be kept in mind.  
Although this review focuses on interactions between NT receptors and heterotrimeric 
G proteins, stimulation of these receptors may also lead to the activation of small G proteins, 
such as Rho-GTPases. Additionally, like other GPCRs, NT receptors probably interact with 
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many other partner proteins and may mediate some G protein-independent signaling events. 
These points will be briefly mentioned.  
Finally, we will also see that, beyond mechanisms underlying NT function, studies on 
interactions between NT receptors and G proteins may also enlighten us on several issues of 
general interest in the field of GPCR modes of action.  
2 Interactions between NTS1 and G proteins 
2.1 One pluripotent receptor, several cells: how to combine economy with diversity 
Common features of NT signaling in all studied natural or transfected systems 
expressing NTS1 were activation of phospholipase C, production of inositol phosphate and 
mobilization of intracellular calcium, suggesting that this receptor was a Gq/11-preferring 
receptor [37]. An involvement of these G proteins in the functional correlates of NTS1 
receptor stimulation was also suggested by experiments showing that intracellular injection of 
an antibody against the common C-terminus of Gq and G11 inhibited the NT-induced 
alterations in function of ion channels [77]. However, NT was also found to induce inhibition 
of adenylyl cyclase and stimulation of arachidonic acid production through interaction with 
Gi/o-type G proteins in selected systems, such as CHO cells transfected with rat or human 
NTS1 [20,53,56] and rat neuroblastoma N1E115 cell line [11]. Furthermore, this peptide 
stimulated adenylyl cyclase through interaction with Gs in cells transfected with rat or human 
NTS1 [62,69,79] and in human pancreatic cancer cells endogenously expressing the receptor 
[31], but not in human colonic adenocarcinoma HT29 cells [1].  
These data clearly indicated that, if NTS1 stimulation could lead to the activation of 
several G proteins, the expression of this potential depended on the host cell. Whether this 
phenomenon reflects differential accessibility to other cellular partners or differential 
compartimentalization of the receptor with G proteins remains to be established. Cell-
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dependence was also observed for more distal intracellular events related to NTS1 
stimulation. For instance, the Gq/11-related activation of the phospholipase C pathway could 
either be followed by an increase in cellular 3', 5'-cyclic guanosine monophosphate (cGMP) 
through activation of soluble guanylyl cyclase [2,70], or trigger a Gs-independent increase in 
cAMP levels through activation of calcium-dependent adenylyl cyclase [14]. Moreover, if NT 
stimulated both phospholipase C and protein kinase C in many cells, this peptide only 
marginally activated the latter branch of this pathway in HT29 cells [12]. Finally, activation 
of mitogen-activated protein kinases (MAPKs) upon NTS1 stimulation in transfected cells or 
some tumor cell lines involved either pertussis-sensitive or insensitive G proteins, or both 
[60]. 
The intracellular events triggered by NT or NT analogs were antagonized by SR 
48692 [37,56]. In that sense, SR 48692 could be considered as an antagonist of all G protein-
mediated consequences of NTS1 stimulation studied so far. One noticeable exception, 
however, was the Ca
2+
-activated Cl
-
 current generated by NT in Xenopus oocytes expressing 
NTS1. Although this effect was generally recognized to be a consequence of the Gq/11-
dependent phospholipase C activation, it was not antagonized by SR 48692 [9]. No 
explanation is yet available for this puzzling finding.  
Some data also suggest that SR 48692 might behave as a NTS1 inverse agonist in 
certain systems. We observed that SR 48692 partially suppressed the constitutive InsP 
formation obtained upon expression of high amounts of NTS1 in sf9 insect cells [7]. 
Moreover, SR 48692 readily reversed the constitutive InsP production observed following 
mutation of the Phe358 residue present in the NTS1 seventh transmembrane domain [4].  
2.2 One receptor, several domains, several G proteins, several ligands: independence and 
combinatorial pharmacology 
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An interesting finding was that the interactions between NTS1 and the diverse G 
proteins involved different receptor domains. Mutations in the NTS1 third intracellular loop 
suppressed agonist-induced InsP production without affecting cAMP accumulation, 
suggesting that this loop was essential for Gq/11 but not Gs activation [80]. Conversely, 
deletion of the receptor C-terminal domain suppressed activation of Gs- but not of Gq/11- 
related signal transduction pathways [28,69]. The receptor C-terminal domain was also shown 
to mediate the activation of Gi/o-related pathways, such as arachidonic acid release [53]. 
Although only based on activation of transduction pathways and not on a direct assessment of 
the physical interaction between the receptor and the corresponding G proteins, these data 
suggest that interaction with Gq/11 involves the NTS1 third intracellular loop, while 
interactions with Gi/o and Gs employ the receptor C-terminal portion. Moreover, the fact that 
deletion or mutation of one intracellular domain completely suppresses some transduction 
pathways while leaving the others unaltered suggests a strikingly high degree of independence 
between functions mediated by individual domains, in spite of their belonging to the same 
protein. This characteristic can be further illustrated by data showing that mutation of the 
Phe358 residue in TM7 of rat NTS1 selectively confers a constitutive activity towards InsP 
but not towards cAMP production [4].  
This possibility of independent activation of the various pathways is of fundamental 
importance for potential design of drugs with targeted pathway selectivity [26,32,33]. Indeed, 
there is no a priori reason that interaction between one receptor and different agonists should 
always result in the same set of domain conformations, leading to parallel degrees of 
activation of the corresponding G proteins. Separation of parameters at the level of the 
receptor molecule itself gives therefore the best potential to find agonist-selective patterns of 
response. This point may be illustrated by our recent demonstration that one NT(8-13) analog, 
EISAI-1, discriminated among pathways involving different NTS1 intracellular domains [69]. 
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When compared with other agonists (NT, neuromedin N and JMV449), this compound 
presented strikingly low relative potency and efficacy to trigger the third intracellular loop-
mediated Gq/11 activation, while being as efficient as other agonists towards the receptor C-
terminal-mediated activation of Gs and Gi/o.(Fig.1) This phenomenon was observed in both 
transfected CHO cells overexpressing NTS1 and rat cortical neurons endogenously expressing 
this receptor, indicating that it did not merely reflect an artifactual situation generated by the 
expression system. The discriminative property of EISAI-1 could be attributed to the 
esterification of its C-terminus, preventing its interaction with Arg
327
, a residue in TM6 which 
was found to play a major role in positioning the neighbouring third intracellular loop for an 
efficacious coupling to Gq/11 [5]. Disruption of this interaction led to an agonist-receptor 
complex that could still efficiently activate Gs and Gi/o, suggesting that it retained an adequate 
conformation of the more distal receptor C-terminus. This result was consistent with the 
existence of several agonist-selective receptor active states, differing in the conformation of 
one or several intracellular domains [32-35,69].  
2.3 One receptor, one G protein: two distinct ways of influencing each other 
Separation of parameters was also evidenced at the level of the bidirectional allosteric 
process that characterizes the receptor-G protein interaction. In this process, the presence of 
one partner or its additional interaction with a ligand may modify the conformation of specific 
domains of the other protein, including  the ligand binding site itself. This process may 
translate into observable changes in the affinity of both kinds of ligands (receptor agonists and 
GTP), which are generally thought to be interdependent. However, data obtained on NTS1 
give a clear illustration that this is not a general rule. 
The ability of a G protein to increase the affinity of receptor agonists represents one of 
the two directions of the interaction process. This phenomenon is usually evidenced by the 
converse decrease in agonist affinity observed when the receptor-G protein interaction is 
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released, which can be achieved in the presence of guanine nucleotides (the “GTP shift”). The 
affinity of radiolabeled NT for wild-type NTS1 was decreased three-to fourfold in the 
presence of the stable GTP analog, GppNHp. Both NT affinity and GppNHp effect were 
strongly reduced after treatment of cell membranes with pertussis toxin, suggesting that the 
main G protein enhancing NT affinity was Gi/o [20]. Furthermore, binding of radiolabeled NT 
to C-terminal truncated NTS1 expressed in CHO cells was totally insensitive to GppNHp, 
although this mutant receptor was still functionally coupled to Gq/11 activation [28]. More 
precisely, the C-terminal truncated receptor kept a high affinity for NT in the presence of 
GppNHp. This observation suggested that, in wild-type NTS1, the C-terminal part constrained 
the receptor in a lower affinity state, which was released by interaction with Gi/o. In the C-
terminal truncated receptor, this constraint was already suppressed, and the presence of Gq/11 
did not further increase NT affinity. Therefore, by contrast with Gi/o, interaction with Gq/11 did 
not appear to greatly alter the affinity of NTS1 agonists. Moreover, these data confirm that 
insensitivity of agonist binding to GTP analogs does not preclude an ability of the agonist-
receptor complexes to trigger G protein activation [28, 33].  
The ability of receptor agonists to increase the binding of GTP to the G proteins, 
indicative of the G protein activation, represents the reverse direction of the allosteric process. 
It may be evaluated by measuring the binding of [
35
S]-GTPS to membrane preparations. NT 
increased the binding of [
35
S]-GTPS in transfected CHO cells expressing rat NTS1 
[20,27,53]. However, although the receptor was coupled to Gq/11, Gi/o and Gs in this system, 
the agonist-induced increase in [
35
S]-GTPS binding was inhibited by pertussis toxin, 
suggesting that this parameter mainly reflected nucleotide exchange at Gi/o [20,53]. This result 
was confirmed by experiments with fusion proteins consisting of various G subunits 
covalently linked to rat NTS1 C-terminus [23].  
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Therefore, in the case of NTS1, the existence of functional receptor-G protein 
interactions was not systematically associated with observable alterations in ligand binding to 
one of the partners. In particular, it appears that sensitivity of receptor agonist binding to GTP 
analogs and "functional coupling of the receptor to a G protein" should be regarded as 
independent parameters. Moreover, from a practical point of view, although most of the 
attention was paid to interactions between NTS1 and Gq/11, it is interesting to notice that the 
two kinds of measurements performed in order to follow the consequences of the receptor-G 
protein interactions were poorly sensitive to the presence of Gq/11, but rather reflected 
interaction between the receptor and Gi/o. 
2.4 Integrating data into theoretical models: how one can be both useless and highly  helpful. 
These data may be discussed in terms of  current models of ligand-receptor-G protein 
interactions, such as the cubic allosteric ternary complex (Fig. 2) [33]. In this model, like in 
the preceding extended ternary complex model [65], "inactive" receptor states are generically 
referred to as "R", and "active" receptor states are termed "R*". Ligands have the ability to 
alter the R*/R ratio, depending on the relative affinity for each receptor state. By contrast with 
the extended ternary complex model [65], the cubic model additionally assumes that both R 
and R* may interact with G proteins. However, by definition, only R* will be able to activate 
the G protein. Thus, this model separates the physical interaction from the activation process, 
which are associated events in the term “coupled to a G protein”. 
In addition to the affinity constants involved in each bimolecular equilibrium, the 
model involves several parameters that characterize the influence of a given molecular species 
on the other partners (Fig.2A). Some parameters are related to the receptor ligand, such as  
(ability of L to alter the R*/R ratio). Some others, such as  (ability of G to alter the R*/R 
ratio) or  (ability of G to alter the affinity of the ligand for R), are related to the G protein. 
However, the values of these parameters are not intrinsic to the molecular species and are 
 1 2  
only valid for interaction with these particular partners. In order to better discriminate 
between the abilities of R* to bind and to activate each G protein, this kind of description 
should be developed taking in account the transition from G to G* with additional parameters, 
such as , representing facilitation of this transition by the active receptor state (Fig.2B). Such 
a development will be particularly important if we want to introduce the possibility that a 
single R*might present different efficacies to activate distinct G proteins.  
Within the limits set by the working capacity of the effector system, the maximal 
effect of a given agonist (Emax) in this system will be proportional to the amount of R*G* at 
saturation of the receptor forms to which it can bind. This amount is governed by the 
efficiency of the agonist and the G protein to induce the R-to-R* transition ( and , 
respectively), the affinities of R and R* for the G protein (KG and ), and the efficacy of R* to 
activate the latter (). The potency (EC50) will reflect a combination of the agonist affinities 
for R, R*, and for their complexes with the G protein. If the effector working capacity reaches 
maximum before saturation ("receptor reserve"), this will produce a leftward shift of the 
EC50 value upon increased receptor expression [33] 
Although such models theoretically provide sets of equations for analysis of 
experimental data, they remain of limited use since several parameter values are difficult to 
obtain experimentally. Moreover, these models do not take in account many important 
parameters, such as oligomerization of the receptor and interaction with other receptors or 
cellular proteins, that could greatly alter the functional responses. Nevertheless, examining 
their properties theoretically and experimentally as best we can may not only help to evaluate 
their accuracy to integrate experimental data but also raise several questions deserving future 
studies. 
A series of comments concerns the effect of G proteins on receptor agonist affinity, 
reflected by the "GTP shift". In accordance with the observation that this phenomenon is 
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independent of G protein activation, these two events are described by different parameters in 
the cubic model. The ability of G to alter the affinity of the ligand for R is represented by , 
while the ability of a ligand to induce G protein activation will be conditioned by parameters 
such as  and . Since these values depend on the ligand, the receptor and the G protein, it 
can be expected that i) the intensity of the GTP shift might differ among agonists, ii) different 
values might be obtained on mutated receptors. Whereas the first point was not yet evidenced, 
greater "GTP shifts" for NT binding were observed following mutations of amino-acids in the 
third extracellular receptor loop [63]. Once again, no correlation could be found between this 
phenomenon and the degree of G protein activation by NT [63].  
An interesting property of  may also be pointed out. As illustrated in Fig. 2A, this 
parameter also reflects the ability of the ligand to alter the affinity of the receptor for the G 
protein. If only Gi/o increases the affinity of NT for NTS1, it can thus be expected that NT 
facilitates formation of the NTS1-Gi/o complex, but not that of NTS1-Gq/11 or NTS1-Gs. This 
would also mean that NTS1 already interacts tightly with both Gq/11 and Gs in the absence of 
ligand. Evaluating the validity of these hypotheses would provide a good support for the 
power of such models to describe the properties of these interactions.  
A second point concerns the differential ability of agonists to activate the various 
signal transduction pathways. This phenomenon, previously termed "agonist-induced 
trafficking of receptor stimulus" [32-35], implied a high degree of independence between the 
activation of the different G proteins [26]. A first possibility to represent the interaction 
between a receptor and two G proteins is to generate a bicubic equation system by adding 
equilibria between R, R* and the second G protein (Fig. 3A). Differential activation of these 
G proteins by one agonist will be described by different values of the parameters traducing the 
ability of the active complex LR* to bind and transconform each G protein. Differences in the 
spectra of G protein activation induced by various agonists will be described through 
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stabilization of different R*s, endowed with different values of these parameters. A second 
proposition was the three-state model [42], in which R was in equilibrium with two active 
states R* and R**, each being able to bind and transconform only one of the G proteins (Fig. 
3B). The ability of a given agonist to differentially activate the two G proteins, as well as 
differences between agonists, will only rely on their relative affinities for each receptor state. 
By contrast with the first approach, this second mode of description does not involve any 
multiplicity of agonist-selective receptor states, since the same R* and R** are considered 
whatever the agonist.  
These two formalisms indeed underlie different assumptions which may not apply to 
all experimental situations. For instance, if the two G proteins interact with different domains 
of the receptor, as observed for Gq/11 and Gs, a single receptor molecule could possibly bind to 
two G proteins (Fig. 1A) and not only to one, as is assumes in the three-state model. 
Moreover, even if we hypothesized that each "active state" in the three-state model 
represented one domain, they could not be linked through successive equilibria since each 
domain is different from the other at a molecular level. Bipotent active receptor states, as 
represented in the bicubic model, seem therefore more accurate to describe such systems. 
From data presented in Fig.1 [69], it can thus be proposed that NT and some other agonists 
stabilize active states collectively referred to as R*1, presenting efficient conformations of 
both the receptor third intracellular loop and C-terminal portion for activation of all G 
proteins, while EISAI-1 stabilizes another class of active states, R*2, endowed with a less 
efficient conformation of the third intracellular loop towards activation of Gq/11. It should be 
noticed that such an hypothesis of multiple agonist-selective active states merely represents 
another expression of the plasticity of the macromolecule already postulated when we 
describe the allosteric transition R/R*.  
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Further examining the properties of the bicubic model brings one to question the 
assumption that successive equilibria link the two receptor-G protein complexes. For instance, 
will the formation of one complex necessarily be achieved at the expense of the other as 
suggested in Figs 3A and 3B? There are at least two scenarios in which this condition would 
be satisfied. The first situation is if one receptor molecule can simultaneously interact with the 
two G proteins. In that case, equilibria with each G protein would join through formation of a 
trimolecular complex, and competition between the two pathways would no longer occur. The 
second situation is if, conversely, we have to consider that the two G proteins interact with 
different non-interconverting receptor forms. These forms might differ in their post-
translational modifications, or represent isolated receptor conformations stabilized by 
different microenvironments in discrete membrane compartments.  
Indeed, recent data suggest that different forms of NTS1 may mediate InsP and cAMP 
production [63]. Although this receptor is often referred to as the "high affinity NT receptor", 
binding experiments performed with the radiolabeled antagonist [3H] SR48692 evidenced 
both the classical high affinity NT site (0.1 nM) and a second class of lower affinity NT sites 
(19 nM). Four mutations in the third extracellular loop resulted in the same kind of 
alterations: an increased proportion of low affinity over high affinity binding sites for NT, a 
30-to 200-fold increase in EC50 for the stimulation of InsP production by NT and a 800- to 
2500-fold increase for cAMP production. As pointed out by the authors [63], the detection of 
two classes of NT affinity suggested the presence of receptor forms which did not equilibrate 
under the experimental conditions. Furthermore, no correlation could be found between the 
relative affinity of NT or number of high affinity NT binding sites within this group of 
receptor mutants and the potencies or maximal effects of NT for activation of either InsP or 
cAMP production. For instance, the relative orders of EC50s and Emax values obtained for 
InsP production correlated with the low affinity site, while the characteristics of cAMP 
 1 6  
production suggested an even lower affinity, yet undetected, NT site. Interestingly, the 
hypothesis of a low NT affinity site mediating InsP production applies not only to these 
mutants, but also to the previously reported mutation at the Asp113 position [45]. However, 
the influence of this mutation on cAMP production was not investigated in the latter study. 
These data on mutated receptors suggest that activations of Gq/11 and Gs may have to 
be considered as involving non-interconverting receptor forms. This would therefore lead to a 
paradoxical description in which, despite each active state of NTS1 being theoretically 
bipotent, the two interactions would have to be formally represented through separate cubes 
(Fig. 4A).  
Such a separate representation of the various pathways does not only apply to mutated 
receptors but would also be necessary to integrate another phenomenon involving the effects 
of EISAI-1 on the wild-type NTS1 [69]. In this study, we observed that a series of agonists 
displayed an inverse order of potencies for stimulating InsP formation as they did for 
enhancing cAMP production. These different pharmacological spectra were due to different 
relative potencies of EISAI-1 in the two assays when compared to other agonists. Indeed, as 
previously noticed [42], no model in which the different G protein-receptor complexes are 
linked by successive equilibria, like in the bicubic or the three-state model, may account for 
altered potency orders between agonists. Whatever the model, and even if the same R and R* 
could be taken for the two pathways, an "isolated pathway" mode [42] should be applied, 
describing the effect of a given agonist on each pathway through separate sets of equations 
(Fig. 4). It remains now to identify the characteristics of the system (compartmentalization of 
the G proteins, sequestration of various receptor populations in discrete plasma membrane 
microdomains, heterogeneity of post-translational modifications) which lead to such an 
apparent lack of equilibrium between the different pathways, and to better understand their 
functional implications at the cellular level.  
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It thus appears that, despite their huge oversimplification, theoretical models taking 
only in account the ligand-receptor-G protein complexes may represent useful tools to 
generate new hypotheses, even on mechanisms occurring under physiological conditions. 
However, such models are clearly not sufficient to integrate all experimental data. In this 
respect, a two-step model, involving the successive formation of metastable NT-NTS1 
complexes and highly stable ligand-receptor adducts, was previously proposed in order to 
describe the role of Na
+
 in modulating the NT-NTS1-G protein interactions in the cell 
environment [52]. Testing the validity of such new hypotheses would probably help us to 
refine our knowledge on the mechanisms underlying agonist-mediated NTS1 activation under 
physiological conditions.  
2.5 Conclusion. 
These considerations illustrate the variety of responses which may arise from the 
interactions between NTS1 and different G proteins, depending on the ligand and the host 
cell. However, this functional diversity may still be underestimated. In this respect, it was 
recently suggested that stimulation of this receptor by NT could also activate members of the 
pertussis-insensitive G12/13 family, triggering the sequential activation of Rho-GTPases and 
NFkB-dependent pathways [82].  
Finally, the functional responses associated with NTS1 can be greatly modified by 
other parameters, such as NTS1 oligomerization or interactions with other receptors and cell 
proteins. For instance, it was recently demonstrated that interaction between NTS1 and NTS3 
decreased the potency of NT to produce InsP and also altered MAPK activation [46]. Most of 
the partners of NTS1, which could alter either its interaction with the G proteins or the 
functional consequences of these interactions, are still unknown. Although a large amount of 
data are now available on NTS1, many points remain to be elucidated. 
 1 8  
3 Interactions between NTS2 and G proteins 
Due to its characteristics (low sensitivity of NT binding to Na
+
, insensitivity to 
guanine nucleotides), the "low affinity NT binding site" had long been considered as a mere 
"acceptor" site for NT, unrelated to any physiological significance [68]. NTS2 was cloned 
from three species: mouse [49], rat [15] and human [76]. However, probably based on this 
history, but also reinforced by its very unexpected properties, recognition of NTS2 as a true 
NT receptor has not been so easy to achieve.  
3.1 One receptor, several cells, several independent pathways; one ligand, several efficacies: 
Very few data are available on signal transduction pathways activated through 
stimulation of mouse NTS2. When this receptor was expressed in Xenopus Laevis oocytes, 
NT, neuromedin N, levocabastine and the NTS1 antagonist, SR 48692, triggered a Ca
2+
-
activated Cl
-
 current, suggesting coupling to Gq/11 in this experimental system [9,49]. 
However, upon expression of the receptor in HEK 293 cells, no alteration of cAMP, cGMP or 
InsP production was observed with either NT or levocabastine [8]. Similarly, no effect of NT 
was evidenced on InsP production when the receptor was expressed in COS cells [45]. SR 
48692 was not evaluated in these last two studies.  
Studies on the cloned human NTS2 [76] extended these first observations, further 
disclosing striking differences between NTS2 and NTS1. When this receptor was expressed in 
CHO cells, stimulation by SR48692 or another NTS1 antagonist, SR 142948A, increased InsP 
formation, calcium mobilization, arachidonic acid production and MAPK activity, but did not 
increase cAMP production [76]. In this study, neither the endogenous peptides, NT and 
neuromedin N, nor levocabastine exerted agonist activity, but instead antagonized the effects 
of the SR compounds. However, in a recent study using the same expression system [21], NT 
was found to increase activation of MAPK, with a lower maximal effect than SR 48692.  
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Another step was achieved through the demonstration that human NTS2 expressed in 
COS cells was constitutively active on InsP production [62]. SR 48692 retained agonist 
activity towards this transduction pathway, NT behaved as a neutral antagonist, and 
levocabastine as a weak partial inverse agonist [62]. When expressed in HEK-293 cells [30], 
human NTS2 constitutively activated serum response element (SRE) signaling through both 
pertussis-sensitive G proteins and Rho-GTPases, suggesting coupling to Gi/o and G12/13-type G 
proteins. Here again, NT behaved as a neutral antagonist on the constitutive signal.  
By contrast with InsP production, human NTS2 expressed in COS cells was not 
constitutively active for Erk1/2 activation [30]. In these cells like in CHO cells, NT increased 
Erk1/2 activation. However, the NT effect was of small amplitude compared with those 
obtained for other receptors of the same family, such as ghrelin receptors [30]. SR 48692 was 
not evaluated in this work. 
Very little is known about cloned rat NTS2 [15]. In a first study on this receptor 
expressed in CHO cells, SR 48692 and levocabastine, but not NT, were found to increase 
intracellular calcium [78]. However, it was further suggested that this effect of SR 48692 was 
NTS2-independent, since it also occurred in mock-transfected cells [21]. A similar rise in 
intracellular calcium by SR 48692 was also found on cultured rat cerebellar granule cells 
endogenously expressing NTS2 [66]. In these cells, no alteration of InsP production was 
observed following stimulation by NT, levocabastine, or SR 48692, and the SR 48692-
induced calcium mobilization was suggested to occur through thapsigargin-sensitive calcium 
stores [66]. Moreover, like in CHO cells, and although cerebellar granule cells expressed 
NTS2, the SR 48692-induced calcium mobilization was suggested to be NTS2-independent, 
since it was not antagonized by NT or levocabastine. These data indicate that effects of SR 
48692 on intracellular calcium should be interpreted with caution, since they may not always 
reflect interaction between this compound and NT receptors. 
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Stimulation of rat NTS2 expressed in CHO cells by NT, neuromedin N, levocabastine 
and SR 48692 increased Erk1/2 activation [21]. Like for the human receptor, which was 
investigated in the same study, the maximal Erk1/2 activation induced by NT was much lower 
than that induced by SR 48692. Interestingly, the SR48692 effect was not reduced upon 
addition of high concentrations of NT, leading to the proposal that the two agents might act 
through different receptor forms [21]. However, it could also be postulated that the NTS2-
independent rise in intracellular calcium induced by SR 48692 in these cells might to some 
extent participate in the SR 48692-induced Erk1/2 activation, which could also account for 
the insensitivity of this effect towards NT application.  
An NT-induced increase in Erk1/2 activation was also found on cultured rat cerebellar 
granule cells endogenously expressing NTS2 [66]. However, a major difference with the 
CHO cell expression system was that no increase in Erk1/2 activation was observed following 
application of SR 48692.  
These data confirmed the coupling potential of NTS2 to diverse signal transduction 
pathways. They showed that the NTS1 antagonist, SR48692, mostly exerted agonist 
properties towards pathways associated with NTS2. They also indicated that the endogenous 
peptides NT and neuromedin N behaved as dual efficacy ligands, antagonizing SR-induced 
activation of several pathways while presenting agonist properties towards MAPK activation. 
3.2 NTS2 signaling and G proteins: only one chapter of the full story? 
Although many data are still lacking, these results may be tentatively interpreted in 
terms of NTS2-G protein interactions.  
It can be suggested that human NTS2 may interact with Gq/11 [30,62,76], Gi/o [30] and 
G12/13 [30]. Whether interaction with Gi/o might account for arachidonic acid release [76], as 
observed with NTS1 [53], remains to be established. By contrast, it seems that this receptor is 
not coupled to Gs, at least from the results obtained on CHO cells [76].  
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Coupling to Gq/11 remains to be confirmed for mouse NTS2, since SR 48692 was not 
tested in the previous studies in HEK and COS cells [8,45], and the question is still open for 
rat NTS2 [21,66]. Nothing is known on a possible interaction between these receptors and Gs, 
Gi/o or G12/13.  
The constitutive activity of human NTS2 towards InsP production [62] and SRE 
signaling [30] suggested a ligand-independent activation of Gq/11, Gi/o and perhaps G12/13. It is 
not clear whether constitutive activity towards InsP production does not occur in CHO cells or 
was just missed in previous studies [76]. Interestingly, a ligand-independent increase in the 
Cl
-
 equilibrium potential had been observed following expression of mouse NTS2 in Xenopus 
laevis oocytes [49], suggesting that this receptor could also lead to constitutive activation of 
Gq/11 in this experimental system. 
 When compared to InsP production, both the lack of constitutive activity observed for 
Erk1/2 activation and the different efficacy exerted by NT provide a striking illustration of the 
independence between pathways already evoked for NTS1. However, a yet unanswered 
question is whether specific G proteins are involved in NTS2-mediated Erk1/2 activation. 
Indeed, several G protein-dependent or independent pathways may be involved in GPCR-
mediated MAPK activation [43]. Erk1/2 activation by SR 48692 in CHO cells was not 
pertussis toxin-sensitive, and was inhibited by overexpression of dominant negative mutant of 
dynamin 1 [21]. Dependence of MAPK activation on dynamin-and/or -arrestin was 
previously reported for other receptors, and was interpreted either as a permissive role of 
internalization [16,51] or, more recently, as a selective role of -arrestins in signaling [73]. 
Interactions between NTS1 and -arrestins were previously reported, involving serine and 
threonine residues in the receptor carboxyl-terminal tail [55], but no such interaction has been 
reported for NTS2. Moreover, whether dominant negative mutant of -arrestin would also 
suppress Erk1/2 activation, similarly to the dynamin mutant, remains to be demonstrated.  
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Furthermore, are some G proteins necessarily involved in these processes? Recent data 
indicate that ligands endowed with inverse agonist activity towards the constitutive activity of 
"classical" G protein-dependent pathways may induce receptor--arrestin interaction and 
MAPK activation, like agonists [3]. However, by contrast with agonists, activation triggered 
by inverse agonists appears to occur through G protein-independent mechanisms [3]. In this 
respect, it would be interesting to evaluate whether such differential mechanisms apply to 
SR48692, NT and levocabastine, which all activate MAPK in CHO cells [21] but behave as 
agonist, neutral antagonist and inverse agonist, respectively, for constitutive InsP production 
in COS cells [62].  
3.3 Conclusion: 
These data indicate that NTS2 may interact with several G proteins. However, by 
contrast with the apparent constancy of the Gq/11-NTS1 receptor interaction from one species 
or one cell to another, no clear preference for a given G protein has yet emerged for NTS2. 
Going further along that line of thought, it might be revealed by future studies that the most 
consistently found signaling pathway is MAPK activation, and that this pathway does not 
involve any G protein, at least for NT itself. Moreover, further studies will be necessary to 
fully elucidate the species-, pathway- and cell-dependence of the constitutive activity 
observed up to now in some experimental systems, and also to identify the receptor domains 
involved in the interactions between NTS2 and the various G proteins.  
It would also be interesting to reconsider the previously called "insensitivity of NTS2 
agonist binding to guanine nucleotides" under the light of all available data. This property was 
previously identified using radolabeled NT as the radioligand. However, we presently know 
that NT acts as a dual efficacy NTS2 ligand and apparently exerts an agonist activity only 
towards MAPK activation, which may not involve any G protein. From the considerations 
developed above for NTS1, we also know that only some G proteins will alter the affinity of 
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some ligands, a property which might be related to the ability of the ligand to favor the 
formation of the receptor-G protein complex. Since SR 48692 and SR142948A appear as the 
most general NTS2 agonists towards Gq/11-, Gi/o- and perhaps G12/13-related pathways, it 
would be interesting to investigate guanine nucleotide sensitivity of radiolabeled SR 48692 or 
SR142948A binding in different cells and receptor mutants allowing separated analysis of 
each receptor-G protein interaction. However, we can already expect that this property might 
appear to be unrelated to the ligand ability to activate the different signaling pathways. 
4. Conclusion 
 Beyond its interest towards a better understanding of NT functions and design of new 
NTergic ligands with potential therapeutic applications, the study of G protein-NT receptor 
interactions emphasizes the wide diversity of signals which may arise from a single GPCR, 
depending on the cell and the ligand [26]. In this respect, NTS2 represents a striking 
illustration of the principle of parameter separation already evidenced for NTS1, at the 
receptor, pathway and ligand levels.  
Whereas NTS1 readily appears as a bona fide NT receptor, this question has long been 
a matter of debate for the "levocabastine-sensitive NT binding site", and remains open due to 
the peculiar properties exhibited by the corresponding receptor, NTS2. However, although NT 
neither activates most NTS2-associated pathways nor alters constitutive activity when it 
occurs, it is now clear that at least one signaling pathway, MAPK activation, may be triggered 
by an interaction of NT with NTS2. This feature was observed not only in experimental 
expression systems but also in natural systems, such as cerebellar granule cells.  
In that sense, there is no longer any problem to classify NTS2 as an NT receptor, 
which may mediate some functions of NT at a physiological level. Nevertheless, it remains 
possible that another endogenous ligand might exist for this receptor, and that some of its 
effects might resemble those displayed by SR 48692. Such a finding would further extend the 
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diversity of functional interactions and responses involving these receptors and our interest in 
devising appropriate models for their description. 
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Legends for Figures. 
 
Figure 1: EISAI-1 discriminates between pathways involving different receptor intracellular 
domains.  
A: Interaction between NTS1 and Gq/11 involves the third receptor intracellular loop, linking 
transmembrane domains V and VI, while interactions with Gs and Gi/o involve the receptor C-
terminal tail following transmembrane domain VII. Whereas NT efficiently activated Gq/11, Gs 
and Gi/o, the NT(8-13) analog EISAI-1 ((Me)Arg-Lys-Pro-Trp-Tle-Leu-O-Et) mostly 
orientates the receptor towards the signaling pathways generated by the last two G proteins. 
This peculiar property of EISAI-1 is due to the esterification of its COOH terminus, 
preventing interaction with Arg327 in TMVI. A high affinity for NTS1 could be retained 
through anchoring of the ethyl moiety in the hydrophobic pocket formed by the 
transmembrane domains.    
B: Illustration of concentration-response curves obtained for the NT(8-13) analogs JMV449 
and EISAI-1 towards InsP production, Arachidonic acid release and cAMP production. When 
compared with JMV449 or other agonists not represented here (NT, neuromedin N or the 
unesterified analog of EISAI-1), EISAI-1 selectively presented both lower relative potency 
and efficacy to activate InsP production. Data taken from [69]. 
 
Figure 2: The cubic allosteric ternary complex model. 
 
A: schematic representation of the model, with identification of some parameters relative to 
the action of the ligand () or the G protein (, ). Note the dual significance of . R, R*: 
generic terms for inactive and active receptor conformations, respectively [33].  
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B: partial representation of the extension of the model, in order to further discriminate 
between binding of R* to G and facilitation by R* of the G/G* transition (activation process). 
A single R* may present different efficacies to activate distinct G proteins. This phenomenon 
will be traduced by different values of the  parameter. 
 
Figure 3: Two ways of representing interaction between one receptor and two G proteins. 
 
A: the bicubic model [33-35]. One active receptor state R* competes for the two G-proteins 
G1 and G2. A single agonist may present different parameter values for each pathway. 
Different agonists may stabilize different R*s, arising from the same or different Rs 
(hypothesis of multiple agonist-selective receptor states). This phenomenon will be traduced 
by different sets of parameters in the respective bicubic models generated for each agonist.  
B: the three-state model [42]. Interaction with each G protein occurs through different 
receptor active states, R* and R**. A given agonist may differentially activate each pathway, 
based on its respective affinities for each receptor state. All agonists stabilize the same couple 
of active states R* and R**, although with different abilities (affinities). Here again, like in 
the bicubic model, formation of one receptor-G protein complex occurs at the expense of the 
other complex, due to the successive equilibria linking all receptor species. 
 
Figure 4: Representing interactions between one receptor and two G proteins through isolated 
pathways.  
A : Schematic representation of the « isolated pathway » mode in the cubic [33] and the three-
state [42] models. This representation involves the same receptor forms or different receptor 
forms in each pathway.  
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B: Schematic representation of inversion of potencies between agonists among two signal 
transduction pathways. Due to the lower relative potency of one of the compounds towards 
pathway 2 (curves with closed triangles), different potency orders are observed among the 
two pathways. Although such a phenomenon was long attributed to the existence  of multiple 
receptor subtypes, it can occur through stimulation of a single receptor linked to multiple 
pathways [33-35, 42, 69]. The bicubic model as well as the three-state model in their “intact 
mode”, presented in Fig. 3, may accomodate differences in maximal effects (“intrinsic 
efficacies”). However, in the absence of receptor reserve for both pathways, only the 
description trough separate sets of equation, avoiding successive equilibria between species, 
may account for different relative potencies between pathways [42]. This situation may be 
due to particular conditions encountered in a given experimental system, such as 
compartmentalization of receptor species with G proteins in discrete membrane 
microdomains.  
 
